p53 in trichostatin A induced C6 glioma cell death

Biochimica et Biophysica Acta - General Subjects

Volumn 1810, Issue 5, 2011, Pages 504-513

  Hsu, Ya Fen ^a   Sheu, Joen Rong ^b,c   Hsiao, George ^b,c   Lin, Chien Huang ^b   Chang, Tsai Hsing ^b   Chiu, Pei Ting ^c   Wang, Chun Yu ^c   Hsu, Ming Jen ^b,c  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Histone deacetylase; p53; Survivin; Trichostatin A

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SIRTINOL; SURVIVIN; TRICHOSTATIN A;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DEPHOSPHORYLATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TRANSACTIVATION; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GLIOMA; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; I-KAPPA B KINASE; MICROTUBULE-ASSOCIATED PROTEINS; MODELS, BIOLOGICAL; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RATS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952711060     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2011.02.006     Document Type: Article

References (62)

1. A.J. Frew, R.W. Johnstone, J.E. Bolden, Enhancing the apoptotic and therapeutic effects of HDAC inhibitors, Cancer Lett 280 (2009) 125-133.
2. A. Mai, L. Altucci, Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead, Int J Biochem Cell Biol 41 (2009) 199-213.
3. T. Ito, Role of histone modification in chromatin dynamics, J Biochem 141 (2007) 609-614. (Pubitemid 47014007)
4. S. Minucci, P.G. Pelicci, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nat Rev Cancer 6 (2006) 38-51. (Pubitemid 43054973)
5. M. Porcu, A. Chiarugi, The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension, Trends Pharmacol Sci 26 (2005) 94-103. (Pubitemid 40170172)
6. M.H. Kuo, C.D. Allis, Roles of histone acetyltransferases and deacetylases in gene regulation, Bioessays 20 (1998) 615-626. (Pubitemid 28422221)
7. T. Kouzarides, Histone acetylases and deacetylases in cell proliferation, Curr Opin Genet Dev 9 (1999) 40-48. (Pubitemid 29080385)
8. M. Dokmanovic, P.A. Marks, Prospects: histone deacetylase inhibitors, J Cell Biochem 96 (2005) 293-304. (Pubitemid 41437862)
9. L. Geng, K.C. Cuneo, A. Fu, T. Tu, P.W. Atadja, D.E. Hallahan, Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer, Cancer Res 66 (2006) 11298-11304. (Pubitemid 46009960)
10. M. Krishnan, A.B. Singh, J.J. Smith, A. Sharma, X. Chen, S. Eschrich, T.J. Yeatman, R. D. Beauchamp, P. Dhawan, HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability, Oncogene (2009).
11. D. Wegener, C. Hildmann, A. Schwienhorst, Recent progress in the development of assays suited for histone deacetylase inhibitor screening, Mol Genet Metab 80 (2003) 138-147. (Pubitemid 37272240)
12. A. Guha, J. Mukherjee, Advances in the biology of astrocytomas, Curr Opin Neurol 17 (2004) 655-662. (Pubitemid 39612996)
13. A. Natsume, Y. Kondo, M. Ito, K. Motomura, T. Wakabayashi, J. Yoshida, Epigenetic aberrations and therapeutic implications in gliomas, Cancer Sci 101, 1331-1336.
14. P.M. Henson, D.A. Hume, Apoptotic cell removal in development and tissue homeostasis, Trends Immunol 27 (2006) 244-250.
15. M.D. Jacobson, M. Weil, M.C. Raff, Programmed cell death in animal development, Cell 88 (1997) 347-354. (Pubitemid 27131376)
16. K. Vermeulen, D.R. Van Bockstaele, Z.N. Berneman, Apoptosis: mechanisms and relevance in cancer, Ann Hematol 84 (2005) 627-639. (Pubitemid 41554237)
17. E. Wang, R. Marcotte, E. Petroulakis, Signaling pathway for apoptosis: a racetrack for life or death, J Cell Biochem Suppl 32-33 (1999) 95-102. (Pubitemid 30041815)
18. S. Mehrotra, L.R. Languino, C.M. Raskett, A.M. Mercurio, T. Dohi, D.C. Altieri, IAP regulation of metastasis, Cancer Cell 17, 53-64.
19. C.W. Lee, C.M. Raskett, I. Prudovsky, D.C. Altieri, Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis, Cancer Res 68 (2008) 5273-5281.
20. D.C. Altieri, Survivin, cancer networks and pathway-directed drug discovery, Nat Rev Cancer 8 (2008) 61-70.
21. G. Ambrosini, C. Adida, D.C. Altieri, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma, Nat Med 3 (1997) 917-921.
22. M.V. Mityaev, E.P. Kopantzev, A.A. Buzdin, T.V. Vinogradova, E.D. Sverdlov, Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter, Biochemistry (Mosc) 73 (2008) 1183-1191.
23. D. Grossman, P.J. Kim, O.P. Blanc-Brude, D.E. Brash, S. Tognin, P.C. Marchisio, D.C. Altieri, Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53, J Clin Invest 108 (2001) 991-999. (Pubitemid 32946073)
24. A. Mirza, M. McGuirk, T.N. Hockenberry, Q. Wu, H. Ashar, S. Black, S.F. Wen, L. Wang, P. Kirschmeier, W.R. Bishop, L.L. Nielsen, C.B. Pickett, S. Liu, Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway, Oncogene 21 (2002) 2613-2622. (Pubitemid 34478319)
25. Y. Jiang, H.I. Saavedra, M.P. Holloway, G. Leone, R.A. Altura, Aberrant regulation of survivin by the RB/E2F family of proteins, J Biol Chem 279 (2004) 40511-40520. (Pubitemid 39287642)
26. N. Cosgrave, A.D. Hill, L.S. Young, Growth factor-dependent regulation of survivin by c-myc in human breast cancer, J Mol Endocrinol 37 (2006) 377-390. (Pubitemid 46085164)
27. X.H. Peng, P. Karna, Z. Cao, B.H. Jiang, M. Zhou, L. Yang, Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression, J Biol Chem 281 (2006) 25903-25914. (Pubitemid 44401796)
28. D. Raj, T. Liu, G. Samadashwily, F. Li, D. Grossman, Survivin repression by p53, Rb and E2F2 in normal human melanocytes, Carcinogenesis 29 (2008) 194-201.
29. P.A. Baeuerle, D. Baltimore, NF-kappa B: ten years after, Cell 87 (1996) 13-20.
30. Z.G. Liu, H. Hsu, D.V. Goeddel, M. Karin, Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death, Cell 87 (1996) 565-576. (Pubitemid 26374329)
31. D.J. Van Antwerp, S.J. Martin, T. Kafri, D.R. Green, I.M. Verma, Suppression of TNF-alpha-induced apoptosis by NF-kappaB, Science 274 (1996) 787-789.
32. S. Bergqvist, C.H. Croy, M. Kjaergaard, T. Huxford, G. Ghosh, E.A. Komives, Thermodynamics reveal that helix four in the NLS of NF-kappaB p65 anchors IkappaBalpha, forming a very stable complex, J Mol Biol 360 (2006) 421-434. (Pubitemid 43927832)
33. Z.W. Li, W. Chu, Y. Hu, M. Delhase, T. Deerinck, M. Ellisman, R. Johnson, M. Karin, The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis, J Exp Med 189 (1999) 1839-1845. (Pubitemid 29272700)
34. M. Delhase, M. Hayakawa, Y. Chen, M. Karin, Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation, Science 284 (1999) 309-313.
35. J.M. Adams, S. Cory, The Bcl-2 apoptotic switch in cancer development and therapy, Oncogene 26 (2007) 1324-1337. (Pubitemid 46328466)
36. T. Miyashita, J.C. Reed, Tumor suppressor p53 is a direct transcriptional activator of the human bax gene, Cell 80 (1995) 293-299.
37. J.R. Jeffers, E. Parganas, Y. Lee, C. Yang, J. Wang, J. Brennan, K.H. MacLean, J. Han, T. Chittenden, J.N. Ihle, P.J. McKinnon, J.L. Cleveland, G.P. Zambetti, Puma is an essential mediator of p53-dependent and -independent apoptotic pathways, Cancer Cell 4 (2003) 321-328. (Pubitemid 37329796)
38. K. Hastak, M.K. Agarwal, H. Mukhtar, M.L. Agarwal, Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate, FASEB J 19 (2005) 789-791. (Pubitemid 40617385)
39. N. Dumaz, D.W. Meek, Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2, EMBO J 18 (1999) 7002-7010. (Pubitemid 30000453)
40. M.J. Hsu, C.Y. Hsu, B.C. Chen, M.C. Chen, G. Ou, C.H. Lin, Apoptosis signal-regulating kinase 1 in amyloid beta peptide-induced cerebral endothelial cell apoptosis, J Neurosci 27 (2007) 5719-5729. (Pubitemid 350021089)
41. S. Sinha, S.K. Malonia, S.P. Mittal, K. Singh, S. Kadreppa, R. Kamat, R. Mukhopadhyaya, J.K. Pal, S. Chattopadhyay, Coordinated regulation of p53 apoptotic targets BAX and PUMA by SMAR1 through an identical MAR element, EMBO J 29, 830-842.
42. Y. Xu, Regulation of p53 responses by post-translational modifications, Cell Death Differ 10 (2003) 400-403. (Pubitemid 36626351)
43. M.A. Glozak, N. Sengupta, X. Zhang, E. Seto, Acetylation and deacetylation of non-histone proteins, Gene 363 (2005) 15-23. (Pubitemid 41691888)
44. P.M. Yang, W.C. Huang, Y.C. Lin, W.Y. Huang, H.A. Wu, W.L. Chen, Y.F. Chang, C.W. Chou, C.C. Tzeng, Y.L. Chen, C.C. Chen, Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis, J Cell Mol Med 14, 687-698.
45. W.C. Huang, T.K. Ju, M.C. Hung, C.C. Chen, Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB, Mol Cell 26 (2007) 75-87.
46. W.S. el-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W. E. Mercer, K.W. Kinzler, B. Vogelstein, WAF1, a potential mediator of p53 tumor suppression, Cell 75 (1993) 817-825.
47. C.T. Kuo, M.J. Hsu, B.C. Chen, C.C. Chen, C.M. Teng, S.L. Pan, C.H. Lin, Denbinobin induces apoptosis in human lung adenocarcinoma cells via Akt inactivation, Bad activation, and mitochondrial dysfunction, Toxicol Lett 177 (2008) 48-58.
48. J.E. Bolden, M.J. Peart, R.W. Johnstone, Anticancer activities of histone deacetylase inhibitors, Nat Rev Drug Discov 5 (2006) 769-784. (Pubitemid 44348499)
49. X.J. Yang, S. Gregoire, Class II histone deacetylases: from sequence to function, regulation, and clinical implication, Mol Cell Biol 25 (2005) 2873-2884.
50. A.Y. Law, K.P. Lai, W.C. Lui, H.T. Wan, C.K. Wong, Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation, Exp Cell Res 314 (2008) 2975-2984.
51. Y.C. Hsu, X. Meng, L. Ou, M.M. Ip, Activation of the AMP-activated protein kinasep-38 MAP kinase pathway mediates apoptosis induced by conjugated linoleic acid in p53-mutant mouse mammary tumor cells, Cell Signal 22 (2010) 590-599.
52. J. Li, E.J. Miller, J. Ninomiya-Tsuji, R.R. Russell 3rd, L.H. Young, AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart, Circ Res 97 (2005) 872-879. (Pubitemid 41552672)
53. N.J. Maclaine, T.R. Hupp, The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway, Aging (Albany NY) 1 (2009) 490-502.
54. A. Papi, A.M. Ferreri, P. Rocchi, F. Guerra, M. Orlandi, Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells, Anticancer Res 30 (2010) 535-540.
55. V. Sharma, N. Koul, C. Joseph, D. Dixit, S. Ghosh, E. Sen, HDAC inhibitor Scriptaid induces glioma cell apoptosis through JNK activation and inhibits telomerase activity, J Cell Mol Med 14 (2010) 2151-2161.
56. H.M. Zhang, J. Yuan, P. Cheung, D. Chau, B.W. Wong, B.M. McManus, D. Yang, Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression, Mol Cell Biol 25 (2005) 6247-6258. (Pubitemid 40946572)
57. D. Hu, S. Liu, L. Shi, C. Li, L. Wu, Z. Fan, Cleavage of survivin by Granzyme M triggers degradation of the survivin-XIAP complex to free caspase activity leading to cytolysis of target tumor cells, J Biol Chem 285 (2010) 18326-18335.
58. P. Wu, Y. Tian, G. Chen, B. Wang, L. Gui, L. Xi, X. Ma, Y. Fang, T. Zhu, D. Wang, L. Meng, G. Xu, S. Wang, D. Ma, J. Zhou, Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells, Cell Death Differ 17 (2010) 109-118.
59. O.H. Kramer, S. Muller, M. Buchwald, S. Reichardt, T. Heinzel, Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha, FASEB J 22 (2008) 1369-1379. (Pubitemid 351656778)
60. E.J. Noh, D.S. Lim, G. Jeong, J.S. Lee, An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner, Biochem Biophys Res Commun 378 (2009) 326-331.
61. S.J. Kim, S.G. Hwang, D.Y. Shin, S.S. Kang, J.S. Chun, p38 kinase regulates nitric oxide-induced apoptosis of articular chondrocytes by accumulating p53 via NFkappa B-dependent transcription and stabilization by serine 15 phosphorylation, J Biol Chem 277 (2002) 33501-33508. (Pubitemid 34984874)
62. A. Puissant, P. Auberger, AMPK- and p62/SQSTM1-dependent autophagy mediate resveratrol-induced cell death in chronic myelogenous leukemia, Autophagy 6 (2010) 655-657.